2024 AAIC Poster

/in , , , , , /by

2024 AAIC Poster:

INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews Among Trial Participants with Early Alzheimer’s Disease
and Their Study Partners

2024 AAIC Poster

/in , , , , , , /by

2024 AAIC Poster:

Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 Study in Early AD

2024 AAIC Poster

/in , , , , , , /by

2024 AAIC Poster:

INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total Sabirnetug (ACU193) in Human CSF

2024 AAIC Poster

/in , , , , , /by

2024 AAIC Poster: 

INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners

2023 AAIC Presentation

/in , , , , , , /by

2023 AAIC Presentation:

 

Topline results of INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.

2022 AAIC Poster

/in , , , /by

2022 AAIC Poster:

 

Preparation and qualification of soluble AβOs for use in bioanalytical assays supporting AD therapeutics.

2019 AAIC Poster

/in , , , /by

2019 AAIC Poster:

 

Soluble Aβ-Oligomer–Selective Antibody ACU3B3 Reduces Amyloid Pathology & Improves Multiple Behavioral Domains in a Mouse Model of AD.